Hydra head activator-like immunoreactivity in human brain astrocytomas grade III-IV and the surrounding brain tissue.

We have developed a specific and sensitive radioimmunoassay for the hydra head activator neuropeptide (HHAP). The antibody recognizes the C-terminal portion of HHAP and shows no cross-reactivity with other neuropeptides. The assay allows measurement of HHAP-like material in tissue extracts with a minimum detectable concentration of 22 fmol/ml standard HHAP (2 fmol/tube). The concentration of immunoreactive (IR) HHAP in histopathologically characterized tissues was determined in 43 specimens from astrocytomas grade III-IV and surrounding brain tissue from 18 patients. Twenty-two control specimens of gray and white matter and five from hypothalamus were taken from 5 brains at autopsy. The concentration of IR-HHAP in the brain tumors, including the actively growing tumor front, is lower than in normal brain, and thus appears not to act as a growth factor. High performance liquid chromatography (HPLC) of extracts of hypothalamus and tumors revealed two major peaks of IR-HHAP; one eluted with the same elution volume as synthetic HHAP. HPLC of cerebral cortex extracts revealed only one major peak of IR-HHAP eluting close to the void volume, which may indicate a posttranslational processing variability of HHAP in different brain regions. By immunocytochemistry HHAP immunoreactivity was localized to the cytoplasma of neuroectodermal cells.